Overview
MGF is the IGF-1Ec splice variant produced locally in muscle after mechanical or eccentric loading. Synthetic MGF mimics the short, immediate-acting form.
- Endogenously produced in loaded muscle
- Synthesized in research laboratories
- Intramuscular injection (research)
Mechanism of action
Acts on satellite cells via a distinct pathway from systemic IGF-1, recruiting them to fuse with damaged fibers and support hypertrophy.
- · Satellite-cell activation
- · Local IGF-1R signaling
- · Local IGF-1 isoform
How it acts on the body
Whenever a muscle fiber is loaded eccentrically, the IGF-1 gene is alternatively spliced to produce IGF-1Ec — MGF — which is released locally and acts on resident satellite cells. Those satellite cells then proliferate and fuse with damaged fibers, contributing to repair and adaptation.
Synthetic MGF attempts to mimic this signal directly. Its systemic half-life is very short, so it is typically dosed locally and timed close to mechanical stimulus. Because the satellite-cell pool is finite and regulated by myostatin and other brakes, the practical hypertrophy effect of exogenous MGF in healthy humans is debated.
Hormonal & endocrine impact
How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.
Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.
Effects on the body
Organ system effects
Local hyperplastic and repair signaling.
Reported effects
Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.
- Tied tightly to load-induced repair mechanism
- Local action limits systemic exposure
Potential side effects
- · Injection-site soreness
- · Mild hypoglycemia
- · Tumor-growth concerns shared with IGF-family peptides
Drug interactions
No notable interactions reported.
Pairing context
- Eccentric or heavy trainingMatches the physiological context MGF evolved for.
- Active malignancyShared IGF-family risk.